Novo Nordisk Investigational Site
Princeton, New Jersey, 08540, United States
NCT Number: NCT00095446
This trial is conducted in the United States of America (USA). The aim of this trial is to assess control of blood sugar, safety, and patient acceptance of insulin aspart compared to insulin lispro, both in insulin pumps, in standard clinical practice.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
Princeton, New Jersey, 08540, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Novo Nordisk A/S
Industry
An Open-Label, Multi Center, Clinical Trial: External Continuous Subcutaneous Infusion of Insulin Using Insulin Aspart (NovoLog®) in Subjects With Type 1 and Insulin Requiring Type 2 Diabetes
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04769167
Autoimmune Diseases, Cardiovascular Abnormalities
St Louis, Missouri, United States
View Trial DetailsNCT00671008
Autoimmune Diseases, Diabetes
Sarajevo, Bosnia and Herzegovina
View Trial DetailsNCT00655200
Autoimmune Diseases, Diabetes
Manila, Philippines
View Trial DetailsNCT00918151
Autoimmune Diseases, Diabetes
Seoul, South Korea
View Trial Details